Apolipoprotein A-I, apolipoprotein B, and apolipoprotein B/apolipoprotein A-I ratio: Reference intervals compared with values in different pathophysiological conditions from the FINRISK 2007 study

Autor: Veikko Salomaa, Jaana Leiviskä, Jouko Sundvall, Matti Jauhiainen, G. Alfthan
Rok vydání: 2011
Předmět:
Adult
Male
medicine.medical_specialty
Very low-density lipoprotein
Apolipoprotein B
Clinical Biochemistry
030204 cardiovascular system & hematology
Risk Assessment
digestive system
Biochemistry
03 medical and health sciences
0302 clinical medicine
Reference Values
Internal medicine
Diabetes mellitus
polycyclic compounds
Humans
Medicine
Disease
Finland
Aged
Apolipoproteins B
030304 developmental biology
0303 health sciences
Apolipoprotein A-I
biology
business.industry
Biochemistry (medical)
nutritional and metabolic diseases
General Medicine
Middle Aged
medicine.disease
Health Surveys
Obesity
Pathophysiology
3. Good health
Reference intervals
Apolipoprotein B/Apolipoprotein A-I
Endocrinology
biology.protein
Female
lipids (amino acids
peptides
and proteins)
Metabolic syndrome
business
Blood Chemical Analysis
Zdroj: Clinica Chimica Acta. 412:1146-1150
ISSN: 0009-8981
DOI: 10.1016/j.cca.2011.03.015
Popis: Background In addition to traditional measurements of serum lipid levels, apolipoprotein A-I (apoA-I), apolipoprotein B (apoB), and apoB/apoA-I ratio may add more value to risk assessment guidelines for cardiovascular disease. Methods We calculated reference intervals for apoA-I, apoB, and apoB/apoA-I ratio using a reference sample (n = 2828) from the FINRISK 2007 study. Results The reference intervals for apoA-I were 1.1–2.0 g/l for men and 1.2–2.3 g/l for women. The corresponding reference intervals for apoB were 0.6–1.5 g/l and 0.6–1.3 g/l. The reference intervals for apoB/apoA-I ratio were 0.3–1.0 for men and 0.3–0.8 for women. Compared with the healthy reference group, obese men had the lowest ApoA-I, the highest apoB, and the highest apoB/apoA-I ratio. Men with CVD and cholesterol-lowering medication, or diabetes had lower apoB levels and apoB/apoA-1 ratio than the reference group but the opposite was true for women. The therapeutic goal for low-risk individuals for apoB was 0.9 g/l coinciding with LDL-C concentration of 3.0 mmol/l. Conclusions Reference intervals for apoA-I, apoB, and the apoB/apoA-I ratio and their cutoff values may be useful for the risk evaluation and follow-up of treatment among individuals having CVD or other metabolic disorders.
Databáze: OpenAIRE
Externí odkaz: